[go: up one dir, main page]

TW200733976A - Method for the treatment of cognitive dysfunction - Google Patents

Method for the treatment of cognitive dysfunction

Info

Publication number
TW200733976A
TW200733976A TW096100409A TW96100409A TW200733976A TW 200733976 A TW200733976 A TW 200733976A TW 096100409 A TW096100409 A TW 096100409A TW 96100409 A TW96100409 A TW 96100409A TW 200733976 A TW200733976 A TW 200733976A
Authority
TW
Taiwan
Prior art keywords
treatment
cognitive dysfunction
patient
hydroxytryptamine
alzheimer
Prior art date
Application number
TW096100409A
Other languages
English (en)
Inventor
Thomas Anthony Comery
Lee Erwin Schechter
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of TW200733976A publication Critical patent/TW200733976A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW096100409A 2006-01-13 2007-01-05 Method for the treatment of cognitive dysfunction TW200733976A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75884106P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
TW200733976A true TW200733976A (en) 2007-09-16

Family

ID=38109582

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096100409A TW200733976A (en) 2006-01-13 2007-01-05 Method for the treatment of cognitive dysfunction

Country Status (20)

Country Link
US (1) US20070167431A1 (zh)
EP (1) EP1971334A2 (zh)
JP (1) JP2009523728A (zh)
KR (1) KR20080096657A (zh)
CN (1) CN101370499A (zh)
AR (1) AR060019A1 (zh)
AU (1) AU2007208516A1 (zh)
BR (1) BRPI0706515A2 (zh)
CA (1) CA2635920A1 (zh)
CR (1) CR10139A (zh)
EC (1) ECSP088619A (zh)
GT (1) GT200800138A (zh)
IL (1) IL192694A0 (zh)
MX (1) MX2008009021A (zh)
NO (1) NO20082894L (zh)
PE (1) PE20071143A1 (zh)
RU (1) RU2008126245A (zh)
TW (1) TW200733976A (zh)
WO (1) WO2007087151A2 (zh)
ZA (1) ZA200806070B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20060100T3 (en) 2003-07-22 2007-03-31 Arena Pharmaceuticals Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
JP2009541423A (ja) * 2006-06-23 2009-11-26 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ
AR061637A1 (es) * 2006-06-26 2008-09-10 Epix Delaware Inc Composiciones y metodos de tratamiento de trastornos del snc
US9084742B2 (en) * 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
WO2009123714A2 (en) 2008-04-02 2009-10-08 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
RU2467749C1 (ru) * 2011-04-21 2012-11-27 Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации Способ коррекции уровня сахара крови и лечения пациентов с сахарным диабетом второго типа с когнитивными нарушениями
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
KR102602947B1 (ko) 2014-11-03 2023-11-16 아이오메트 파마 엘티디 제약 화합물
MX2017014191A (es) * 2015-05-07 2018-08-01 Axovant Sciences Gmbh Metodos de tratamiento de una enfermedad neurodegenerativa.
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
US20170246163A1 (en) * 2016-02-25 2017-08-31 Axovant Sciences Gmbh Methods of improving balance, gait or both in patients with neurological disease
SMT202300197T1 (it) * 2016-04-26 2023-09-06 H Lundbeck As Uso di un inibitore di acetilcolinesterasi e idalopirdina per ridurre cadute in pazienti con morbo di parkinson.
US10864191B2 (en) * 2016-05-11 2020-12-15 H. Lundbeck A/S 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity
SMT202000292T1 (it) 2016-05-18 2020-07-08 Suven Life Sciences Ltd Combinazione di antagonisti del recettore di 5-ht6 puri con inibitori delle acetilcolinesterasi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343756A2 (en) * 2000-11-02 2003-09-17 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
JP2006510662A (ja) * 2002-12-11 2006-03-30 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体アゴニストとその他の化合物との組合せによる疾患の治療
WO2004074243A2 (en) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
NZ565872A (en) * 2005-08-15 2011-06-30 Wyeth Corp Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands

Also Published As

Publication number Publication date
CN101370499A (zh) 2009-02-18
PE20071143A1 (es) 2008-01-20
NO20082894L (no) 2008-09-30
AU2007208516A8 (en) 2008-08-07
RU2008126245A (ru) 2010-02-20
ECSP088619A (es) 2008-08-29
US20070167431A1 (en) 2007-07-19
KR20080096657A (ko) 2008-10-31
WO2007087151A2 (en) 2007-08-02
CR10139A (es) 2008-09-30
MX2008009021A (es) 2008-09-24
IL192694A0 (en) 2009-02-11
JP2009523728A (ja) 2009-06-25
AU2007208516A1 (en) 2007-08-02
CA2635920A1 (en) 2007-08-02
GT200800138A (es) 2008-10-06
EP1971334A2 (en) 2008-09-24
AR060019A1 (es) 2008-05-21
ZA200806070B (en) 2009-04-29
WO2007087151A3 (en) 2007-11-15
BRPI0706515A2 (pt) 2011-03-29

Similar Documents

Publication Publication Date Title
WO2007087151A3 (en) Combination of ache inhibitor and 5-ht6 antagonist for the treatment of cognitive dysfunction
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
ATE510538T1 (de) Zusammensetzungen und verfahren für nervenschutz
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
TW200716546A (en) Oxindole compounds and their uses as therapeutic agents
TW200602048A (en) Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase
MY161991A (en) Proteasome inhibitors
WO2008008551A3 (en) 2-substituted proline bis-amide orexin receptor antagonists
TW200531689A (en) Therapeutic agents
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
MX2008012400A (es) Azolopirimidinas como inhibidores de actividad de cannabinoide 1.
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
ZA200806778B (en) N-Hydroxyacrylamide compounds
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
MX2009003981A (es) Agentes moduladores del receptor de calcio.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
WO2009043858A3 (en) Methods for treating and diagnosing a cancer secreting cath-d or alzheimer's disease
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
EP2084178A4 (en) CONJUGATES OF CYTOTOXIC COMPOUNDS WITH PEPTIDES